FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies By Ogkologos - August 12, 2026 99 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Precision-T study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... May 7, 2021 Significant PFS Benefit in Patients with HR-positive, HER2-negative MBC Who Switched... May 26, 2023 Beloved Jeopardy! Host Alex Trebek Has Passed Away After Battle with... November 9, 2020 FDA Approves Cemiplimab-rwlc for Advanced Non-Small Cell Lung Cancer With High... February 23, 2021 Load more HOT NEWS Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... Nivolumab Does Not Prolong Overall Survival Compared with Sorafenib In First-Line... ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... Stiff “Hot Spots” Within Tumors Help Doctors Predict Spread of Breast...
